Brief: Oncolytics reports additional data from phase II study of Reolysin
Aug 10 (Reuters) - Oncolytics Biotech Inc ONC.TO
* Oncolytics Biotech Inc. reports additional data from
randomized phase II study of Reolysin in non-small cell lung
cancer
* Study demonstrates statistically significant improvement
in progression free survival in female patients with
Adenocarcinoma
* Based on findings from IND 211, intends to include
preselection of patients using genetic screening in future study
protocols
Source text for Eikon: urn:newsml:reuters.com:*:nCNWjBzD9a
Further company coverage: ONC.TO
((bangalore.newsroom@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Announces Clinical Supply Agreement To Evaluate Pelareorep In Combination With Loqtorzi In Squamous Cell Anal Carcinoma
Brief: Oncolytics Says Pelareorep Shows Durable Survival Benefit in Anal Cancer
Brief: Oncolytics Biotech Expects Final Cohort 4 Results Of Goblet Study In Q4 2026
Brief: Oncolytics Biotech® Secures Patent Protection To Late 2040S And Provides Intellectual Property Portfolio Update
Brief: Oncolytics Biotech® Aligns With FDA On Registrational Path For Second-Line Ras-Mutant Mss Colorectal Cancer